409 filings
Page 6 of 21
8-K
wn3tw3t3
10 Apr 17
Innoviva Announces $50 Million Partial Royalty Notes Redemption
12:00am
8-K
dog6 5evz9hrc6df
7 Mar 17
Innoviva Files Preliminary Proxy Materials for 2017 Annual Meeting
12:00am
8-K
sxig28df0wza1s
23 Feb 17
Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma
12:00am
8-K
f9hk5yqnbaiko9dqo5
9 Feb 17
Innoviva Reports Fourth Quarter and Full Year 2016 Financial Results
12:00am
8-K
btps1gv2sqc
30 Jan 17
Other Events
12:00am
8-K
ofsrook
2 Dec 16
Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD
12:00am
8-K
0wnkzr3w537k7
2 Dec 16
Other Events
12:00am
8-K
cpnegfczicl z9yhilq9
21 Nov 16
GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD
12:00am
8-K
kpx40yi23 tlc
27 Oct 16
Innoviva Reports Third Quarter 2016 Financial Results
12:00am
8-K
5rg8p1
6 Sep 16
Regulation FD Disclosure
12:00am
8-K
ne261bccwlhb
6 Sep 16
Positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress
12:00am
8-K
zk30fi00
28 Jul 16
Innoviva Reports Second Quarter 2016 Financial Results
12:00am
8-K
s7295
20 Jun 16
Other Events
12:00am
8-K
r2gbhyo d60321j5t
10 Jun 16
Entry into a Material Definitive Agreement
12:00am
8-K
qkq 4xg1m5j
2 Jun 16
Regulatory update on US filing plans for closed triple combination therapy FF/UMEC/VI in patients with COPD
12:00am
8-K
3a7ffoppp rc203
24 May 16
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice
12:00am
8-K
r7gaot
18 May 16
Regulation FD Disclosure
12:00am
8-K
44f47075 seh
28 Apr 16
Innoviva Reports First Quarter 2016 Financial Results
12:00am
8-K
wxoz0uvc7z4n7v
20 Apr 16
Departure of Directors or Certain Officers
12:00am
8-K
cxe28
8 Mar 16
Regulation FD Disclosure
12:00am